일본의 연속 혈당 모니터링 기기 : 시장 점유율 분석, 산업 동향 및 통계, 성장 예측(2024-2029년)

The Japan Continuous Glucose Monitoring Devices Market size is estimated at USD 96.12 million in 2024, and is expected to reach USD 186.25 million by 2029, growing at a CAGR of 10.99% during the forecast period (2024-2029).

COVID-19 disrupted all aspects of the diabetes industry worldwide and in Japan. Several companies faced disruptions in supply and distribution channels nationwide since most of the CGM device components were manufactured outside of Japan. This created a gap between the supply and demand of the devices wherein the limited inventory was available. As a result, the impact of COVID-19 was considerable concerning access to a persistent continuum of care among the Japanese diabetic population. For instance, as per the primary insights, "Almost all Japanese diabetes patients visited their hospital or clinic every 2-3 months despite the COVID-19 pandemic. However, HCPs had limited communication with their patients, which impacted the consumer base and made it difficult to gain new users. In addition, the companies dealing in diabetes care were shut down, and patients visiting hospitals/clinics were unable to provide the product's information to HCPs" (Registered Nurse, Diabetes Care Japan, Lifescan).

Diabetes is a chronic condition marked by high blood glucose levels. It is caused either by the inability to produce insulin (a hormone made by the pancreas to keep blood glucose levels in range) or by the body not being able to use insulin effectively, or both.

Type 1 diabetic patients need to take insulin throughout their lives and maintain a healthy diet and regular physical exercise. Whereas Type 2 diabetic patients need to eat healthily, be physically active, and test their blood glucose level, and may also need to take oral medication and insulin to control the glucose level in their blood. The need for monitoring blood glucose levels is on the rise among diabetic patients, mainly to avoid complications, such as cardiovascular diseases, stroke, blood disorders, blindness, and kidney disorder, among others.

Various CGM devices are available in the japan market. Dexcom develops and manufactures the current-generation G6 CGM. Terumo markets the G6 in Japan. The Dexcom G6 system features a wearable sensor attached to a user's abdomen. It automatically transmits glucose measurements every five minutes to a monitor or smart device with a dedicated application. Users can check their real-time glucose values and trends through a visualized graph. Additionally, G6 notifies users when glucose measurements fall outside a pre-set target range. It also sends alerts upon predictions of hypoglycemia occurring in 20 minutes.

Japan Continuous Glucose Monitoring Devices Market Trends

The Durables Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period

A transmitter is a component of a sensor that sends the blood glucose levels to the reader, receiver, or smartphone app. Receivers are devices that receive data from transmitters and display the results on different user interfaces. The way these components of CGM devices work varies according to their manufacturers. These devices can be visible and may be required to be placed on the skin. Transmitter batteries may be rechargeable or disposable. The market segment is expected to witness growth as a result of the growing use of CGM devices among the diabetic population, growing underlying causes resulting in diabetes, market availability of these products, advantages offered by these durables, and surge in awareness regarding the use of CGM devices among the Japanese population.

Diabetes has been identified as a healthcare priority by the Japanese Ministry of Health, Labour, and Welfare. The high prevalence of type 2 diabetes is associated with a significant economic burden. Costs increase with an increasing number of complications. Well-organized medical insurance systems cover all medical fees for diabetes mellitus, and diabetics can visit doctors freely in Japan.

Rising diabetes prevalence in Japan driving the market in the forecast year

The type 1 diabetic population in Japan is expected to increase, registering a CAGR greater than 0.4% over the forecast period.

There has been a rapid increase in the growth of diabetes in Japan. As per the IDF 2021 estimates, 11 million adults in Japan have diabetes. The objectives of diabetes management are to improve metabolic dysfunctions resulting from hyperglycemia to prevent the development or progression of diabetic complications and conditions associated with diabetes, and to enable affected individuals to maintain their quality of life and life expectancy at a level comparable to those in healthy individuals.

The Japan Diabetes Society (JDS) has set an HbA1c control target of 'less than 7.0%.' At the same time, treatment guidelines developed by the JDS recommend that the general treatment target for HbA1c should be individualized according to treatment risks and patient characteristics.

As the prevalence of diabetes increases, the condition itself and the associated complications generate a considerable and increasing economic burden on the healthcare system and society. Japan is reflecting this trend, facing a growing prevalence of T2D and T1D in the population, with an overall diabetes prevalence rate of 9.7%, as per the data published by a Kobe University study in February 2023. The potential opportunities that diabetes could generate, both in a present and future setting, are profitable for all stakeholders, ultimately creating numerous possibilities for the companies operating within the market.

Hence, the demand for continuous glucose monitoring devices and their adoption rate is also increasing. These factors are expected to drive the market studied.

Japan Continuous Glucose Monitoring Devices Industry Overview

The Japanese continuous glucose monitoring devices market is highly consolidated. Market leaders such as Dexcom, Abbott, and Medtronic are focusing on product launches and technological collaboration to increase their foothold in the market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Dynamics
  • 4.2.1 Market Drivers
  • 4.2.2 Market Restraints
• 4.3 Industry Attractiveness - Porter Five Forces
  • 4.3.1 Bargaining Power of Suppliers
  • 4.3.2 Bargaining Power of Consumers
  • 4.3.3 Threat of New Entrants
  • 4.3.4 Threat of Substitute Products and Services
  • 4.3.5 Intensity of Competitive Rivalry

5 Market Segmentation

• 5.1 By Component
  • 5.1.1 Sensors
  • 5.1.2 Durables (Receivers and Transmitters)
• 5.2 CGM Device Users
  • 5.2.1 Hokkaido
  • 5.2.2 Tohoku
  • 5.2.3 Kanto
  • 5.2.4 Chubu
  • 5.2.5 Kansai
  • 5.2.6 Chugoku
  • 5.2.7 Shikoku
  • 5.2.8 Kyushu
• 5.3 By Provinces
  • 5.3.1 Hokkaido
  • 5.3.2 Tohoku
  • 5.3.3 Kanto
  • 5.3.4 Chubu
  • 5.3.5 Kansai
  • 5.3.6 Chugoku
  • 5.3.7 Shikoku
  • 5.3.8 Kyushu
• 5.4 Market Share by Public and Private
• 5.5 Analysis of CGM Devices Distribution Channels (Includes percentage share of Hospitals, clinics, Pharmacies, and other modes (2022))
• 5.6 Analysis of CGM devices prescribers (includes percentage share of Endocrinologists, Diabetologist, and other HCP specialties (2021), and Prescribers knowledge of CGM devices)

6 Market Indicators

• 6.1 Type-1 Diabetes Population
• 6.2 Type-2 Diabetes Population

7 COMPETITIVE LANDSCAPE

• 7.1 Company Profiles
  • 7.1.1 Abbott Diabetes Care Inc.
  • 7.1.2 Dexcom Inc.
  • 7.1.3 Medtronic PLC
  • 7.1.4 Eversense
  • 7.1.5 Ascensia
• 7.2 Company Share Analysis
  • 7.2.1 Abbott Diabetes Care Inc.
  • 7.2.2 Dexcom Inc.
  • 7.2.3 Medtronic PLC
  • 7.2.4 Other Companies

8 MARKET OPPORTUNITIES AND FUTURE TRENDS